Navigation Links
Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research
Date:4/20/2009

PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced preliminary data from an ongoing Phase 1 clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma (HL) that demonstrated both clinical and immunological activity signals. MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers. Results from the study were presented in a poster session (Abstract #1227) at the Annual Meeting of the American Association for Cancer Research (AACR), held April 18-22, 2009 in Colorado.

An ongoing multi-dose, dose-escalation Phase 1 trial of MDX-1401 in patients with relapsed or refractory HL is being conducted to establish and evaluate the safety profile and initial efficacy of MDX-1401. Preliminary data from the Phase 1 trial demonstrate that multiple doses (ranging from 0.01 to 1.0 mg/kg) of MDX-1401 in patients with HL were generally safe and well-tolerated. Two of the 8 patients with stable disease had a reduction of 40 percent or more in tumor burden after two treatment cycles of MDX-1401. In addition, flow cytometry indicated decreased circulating CD30 positive cells in 83 percent of patients (10/12) after one cycle of four weekly intravenous infusions.

"We find these preliminary safety and efficacy data for our second generation anti-CD30 antibody encouraging," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "We are currently enrolling additional patients at higher dose levels and look forward to examining further results from the ongoing Phase 1 trial."

Information about the AACR and its Annual Meeting may be found at www.aacr.org.'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... liver is one of the most important organs in ... we utilize our food properly this is its ... from our organism this is its detoxification function. ... unhealthy food all damage the liver. The resulting diseased ... cirrhoses, and life-threatening liver failure. According to the German ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
(Date:7/9/2014)... The occurrence of allergic diseases has risen dramatically in ... are less exposed to microorganisms and have fewer infections ... system. , A study by researchers at Sahlgrenska Academy, ... three to examine maturation of the immune system in ... in rural areas of the Vstra Gtaland Region, half ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... Many hospitals in India are opting for high-tech scanners ... comparatively costlier. These high-tech scanners are capable of capturing ... // ,In less than 15 months of ... Healthcare, three leading Indian hospitals have invested in the ...
... drug for breast cancer victims is denied by the NHS ... but the private medical insurers have saved their day by ... already made available this drug to almost 100 women, who ... has made the drug available in 30 such cases. ...
... biggest supermarket, TESCO, was in public glare for the wrong reasons, ... land and for not being party to a movement that promotes ... Agency got after Tesco, soon after the latter rejected the proposition ... made profits of over ?2 billion last year and a turnover ...
... in the forefront, monitoring the Herculean task of culling of ... of the dealers. // This is being done to ascertain ... in safe custody. 20 teams comprising of officials and animal ... civic officials. ,The teams will be checking the ...
... pledged to donate his body for the "advancement of ... Roy said that, "The chief minister has always been ... with which Bhattacharya signed his formal pledge on March ... Basu, Somnath Chatterjee, Anil Biswas and Biman Bose who ...
... Glasgow and discussing on the issue of how to ... programmes and rehabilitation// services. This is the fourth annual ... by day in UK. It was very disturbing when ... Neil Hunter, Glasgow Addiction Services Partnership, said that there ...
Cached Medicine News:Health News:Hospitals In India Opt For High-tech Scanners 2
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WIRE)--May 23, 2007 -,ProtoKinetix Inc. (OTCBB:PKTX) has just ... Inc. at the University of Finland.,These outstanding results ... demonstrate the vital importance of this,molecule in the ... series of tests using AAGP(TM) on human embryonic ...
... Therapeutics,(OTCBB:MIVT) (FWB:MIV), a leading developer of next ... for,Cardiovascular stents and other implantable medical devices, ... animal trial comparing its,proprietary polymer free Hydroxyapatite-coated ... be presented at,this weeks EuroPCR 2007 conference ...
Cached Medicine Technology:ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 2MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 3MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 4
Ballard trach care HMES and filters, tv1000, HME...
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Indications For Usage: , ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hou...
Indications For Usage:, ,Single use on tracheostomy patients who can breathe spontaneously. The product is intended to be replaced at least once every 24 hours....
Medicine Products: